August 19, 1997Circulation
Glucose-Insulin-Potassium Therapy for Treatment of Acute Myocardial Infarction
Why the study?
Does glucose-insulin-potassium (GIK) therapy reduce hospital mortality in patients with acute myocardial infarction?
Population
1,932 patients with acute myocardial infarction pooled from 9 randomized placebo-controlled trials
Comparison
Glucose-insulin-potassium (GIK) therapy vs Placebo
Design
Meta-analysis, randomized, placebo-controlled
Follow-up
in-hospital
Authors
Discussion
Loading...
Member takes
Implication
GIK may reduce AMI hospital mortality; leaves open its role in the modern reperfusion era.
Structured PICO
Does glucose-insulin-potassium (GIK) therapy reduce hospital mortality in patients with acute myocardial infarction?
P
Population
1,932 patients with acute myocardial infarction pooled from 9 randomized placebo-controlled trials
I
Intervention
Glucose-insulin-potassium (GIK) therapy
C
Comparator
Placebo
O
Outcome
Hospital mortalityhard clinical
A meta-analysis of 9 trials suggests that glucose-insulin-potassium therapy significantly reduces in-hospital mortality in patients with acute myocardial infarction, though its relevance in the modern reperfusion era requires further study.
Limitations
- Small number of patients recruited in individual trials
- Discrepancies between protocols used in individual studies
- Uncertain value in the modern era of thrombolysis and acute revascularization by primary angioplasty
Cite This Study
Fath‐Ordoubadi et al. (1997) studied this question.